StockTipsArenaBeta

BUY Gland Pharma Limited — Manas Jaiswal

BUYGland Pharma Limited
Gland Pharma share price target & all analyst calls

byManas JaiswalHorizon: NA (inferred Intraday)9 Nov 2026, 10:16 am ISTvia CNBC Awaaz.

Entry₹3,352.2Inferred
Target₹3,450
Total upside +2.92% (call closed)
Stop loss₹3,250-3.05% risk
At expiry₹3,279.99 Nov 2026, 3:20 pm
Expired-2.16%
Follow Manas Jaiswal for new calls(13% target hit, 171 closed calls)Get alertsWatch GLAND for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 9 Nov 2026
7 supporting1 neutral0 opposing
Supports the BUY call (7)

Gland Pharma shares jump 7% to 52-week high; Nomura sees re-rating but Citi says 'sell'

NewsCnbc-Tv18·9 Nov · today

(opens in new tab)

Gland Pharma shares hit 52-week high; jump 7% despite market sell-off | Will rally continue after 93% YTD rise?

NewsLivemint·9 Nov · today

(opens in new tab)

Gland Pharma Q2 Results: Net profit jumps 58% on strong business execution, CDMO revenue up 31%

NewsCnbc-Tv18·6 Nov · 2d ago

(opens in new tab)

Gland Pharma reported Q2 FY27 financial results with a 23% year-on-year increase in revenue to 18,336 million and a 58% year-on-year increase in profit after tax to 2,908 million.

NSE · Press Release·6 Nov · 2d ago

(opens in new tab)

Gland Pharma reported Q2 FY27 financial results with revenue increasing 23% year-on-year to ₹18,336 million and profit after tax growing 58% year-on-year to ₹2,908 million.

BSE · Company Update·6 Nov · 2d ago

(opens in new tab)
Neutral / worth noting (1)

Gland Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·6 Nov · 2d ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Gland Pharma

All analyst calls on Gland Pharma

More from Manas Jaiswal

Every call and its outcome